Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This study evaluates whether PegIFN alfa-2a add on can improve CHB patients HBsAg clearance
at the end of 48 weeks treatment. The CHB patients who received nucleot(s)ides anti-virus
treatment and reached HBV DNA<1000 copies/ml and HBsAg<3000 IU/ml, were randomly assigned
into two groups: One group continue the nucleot(s)ides treatment for 72 weeks, the other add
on PegIFN alfa-2a on the basis of the original treatment for 48 weeks, and follow up for 24
weeks.
Phase:
Phase 4
Details
Lead Sponsor:
The Second Affiliated Hospital of Chongqing Medical University
Collaborators:
First Affiliated Hospital of Xinjiang Medical University People's Hospital of Guizhou Province The First Affiliated Hospital of Nanchang University